Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 1(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06195618Phase 1Not Yet Recruiting

Personalized Vaccine for TNBC Immunotherapy

Role: collaborator

NCT04105582Phase 1Completed

Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells

Role: collaborator

NCT04879888Phase 1Completed

Personalized Vaccine for Cancer Immunotherapy

Role: collaborator

NCT04344548Phase 1Withdrawn

Adoptive Cell Transfer for the Immunotherapy of COVID-19 in Colombia

Role: collaborator

NCT04346329Phase 3Withdrawn

Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19

Role: collaborator

NCT03450044Phase 1Completed

Immunogenicity and Safety of DCs in Breast Cancer

Role: lead

All 6 trials loaded